<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04233216</url>
  </required_header>
  <id_info>
    <org_study_id>8591A-019</org_study_id>
    <secondary_id>MK-8591A-019</secondary_id>
    <secondary_id>2019-000588-26</secondary_id>
    <secondary_id>205243</secondary_id>
    <nct_id>NCT04233216</nct_id>
  </id_info>
  <brief_title>Doravirine/Islatravir (DOR/ISL) in Heavily Treatment-Experienced (HTE) Participants for Human Immunodeficiency Virus Type 1 (HIV-1) Infection (MK-8591A-019)</brief_title>
  <official_title>A Phase 3, Randomized, Clinical Study in HIV-1-Infected Heavily Treatment-Experienced Participants Evaluating the Antiretroviral Activity of Blinded Islatravir (ISL), Doravirine (DOR), and Doravirine/Islatravir (DOR/ISL), Each Compared to Placebo, and the Antiretroviral Activity, Safety, and Tolerability of Open-Label DOR/ISL</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a 2-part, phase 3 clinical study evaluating the antiretroviral activity and&#xD;
      safety/tolerability of islatravir (ISL), doravirine (DOR), and a fixed dose combination (FDC)&#xD;
      of DOR/ISL (also known as MK-8591A) in heavily treatment-experienced (HTE) participants with&#xD;
      human immunodeficiency virus type 1 (HIV-1) infection. It is hypothesized that the percentage&#xD;
      of participants receiving DOR/ISL to achieve ≥0.5 log10 decrease in HIV-1 ribonucleic acid&#xD;
      (RNA) from study baseline (Day 1) to Day 8 is superior to placebo, each given in combination&#xD;
      with failing antiretroviral therapy (ART).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Part 1 of this study (Day 1 to Day 7) is the double-blind period in which participants&#xD;
      receive either ISL, DOR, DOR/ISL, or placebo. Part 2 of this study (Day 8 to Week 97) is the&#xD;
      open-label period in which all participants receive DOR/ISL + optimized background therapy&#xD;
      (OBT).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 18, 2020</start_date>
  <completion_date type="Anticipated">August 1, 2025</completion_date>
  <primary_completion_date type="Anticipated">July 12, 2024</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of participants receiving doravirine/islatravir (DOR/ISL) with ≥0.5 log10 decrease from baseline in human immunodificiency virus type 1 (HIV-1) ribonucleic acid (RNA) compared to placebo treatment</measure>
    <time_frame>Day 1 (baseline) and Day 8</time_frame>
    <description>The change from baseline in HIV-1 RNA will be determined at the central laboratory with an Abbott Real Time Polymerase Chain Reaction (PCR) assay with a lower limit of detection (LLOD) of 40 copies/mL.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of participants with ≥1 adverse events (AEs)</measure>
    <time_frame>Up to 49 weeks</time_frame>
    <description>An AE is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of participants withdrawing from study treatment due to AE(s)</measure>
    <time_frame>Up to 49 weeks</time_frame>
    <description>An AE is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants with ≥1 adverse events (AEs)</measure>
    <time_frame>Up to 97 weeks</time_frame>
    <description>An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants discontinuing from study therapy due to AE(s)</measure>
    <time_frame>Up to 97 weeks</time_frame>
    <description>An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants receiving DOR or ISL (given with antiretoviral therapy [ART]) with ≥0.5 log10 decrease in HIV-1 RNA compared to placebo treatment</measure>
    <time_frame>Day 1 (baseline) and Day 8</time_frame>
    <description>The percentage of participants with ≥0.5 log10 change from baseline in HIV-1 RNA will be determined. The central laboratory will measure plasma HIV-1 RNA using an Abbott Real Time PCR assay with a LLOD of 40 copies/mL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change from baseline in HIV-1 RNA following treatment with DOR/ISL (given with ART), DOR, or ISL compared to placebo treatment</measure>
    <time_frame>Day 1 (baseline) and Day 8</time_frame>
    <description>The mean change from baseline in HIV-1 RNA will be determined. The central laboratory will measure plasma HIV-1 RNA using an Abbott Real Time PCR assay with a LLOD of 40 copies/mL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants receiving DOR/ISL (given with ART), DOR, or ISL with ≥1.0 log10 decrease from baseline in HIV-1 RNA compared to placebo treatment</measure>
    <time_frame>Day 1 (baseline) and Day 8</time_frame>
    <description>The percentage of participants with ≥1.0 log10 change from baseline in HIV-1 RNA will be determined. The central laboratory will measure plasma HIV-1 RNA using an Abbott Real Time PCR assay with a LLOD of 40 copies/mL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants receiving DOR/ISL (given with ART) with ≥0.5 log10 decrease from baseline in HIV-1 RNA compared to DOR or ISL treatment</measure>
    <time_frame>Day 1 (baseline) and Day 8</time_frame>
    <description>The percentage of participants with ≥0.5 log10 change from baseline in HIV-1 RNA will be determined. The central laboratory will measure plasma HIV-1 RNA using an Abbott Real Time PCR assay with a LLOD of 40 copies/mL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change from baseline in HIV-1 RNA following treatment with DOR/ISL (given with ART) compared to DOR or ISL treatment</measure>
    <time_frame>Day 1 (baseline) and Day 8</time_frame>
    <description>The mean change from baseline in HIV-1 RNA will be determined. The central laboratory will measure plasma HIV-1 RNA using an Abbott Real Time PCR assay with a LLOD of 40 copies/mL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants receiving DOR/ISL (given with ART) with ≥1.0 log10 decrease from baseline in HIV-1 RNA compared to DOR or ISL treatment</measure>
    <time_frame>Day 1 (baseline) and Day 8</time_frame>
    <description>The percentage of participants with ≥1.0 log10 change from baseline in HIV-1 RNA will be determined. The central laboratory will measure plasma HIV-1 RNA using an Abbott Real Time PCR assay with a LLOD of 40 copies/mL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants receiving DOR/ISL (given with ART) + OBT with ≥0.5 log10 decrease from baseline in HIV-1 RNA compared to DOR or ISL treatment</measure>
    <time_frame>Day 8 (baseline) and Week 25</time_frame>
    <description>The percentage of participants with ≥0.5 log10 change from baseline in HIV-1 RNA will be determined. The central laboratory will measure plasma HIV-1 RNA using an Abbott Real Time PCR assay with a LLOD of 40 copies/mL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants receiving DOR/ISL (given with ART) + OBT with ≥0.5 log10 decrease from baseline in HIV-1 RNA compared to DOR or ISL treatment</measure>
    <time_frame>Day 1 (baseline) and Week 49</time_frame>
    <description>The percentage of participants with ≥0.5 log10 change from baseline in HIV-1 RNA will be determined. The central laboratory will measure plasma HIV-1 RNA using an Abbott Real Time PCR assay with a LLOD of 40 copies/mL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants receiving DOR/ISL (given with ART) + OBT with ≥0.5 log10 decrease from baseline in HIV-1 RNA compared to DOR or ISL treatment</measure>
    <time_frame>Day 1 (baseline) and Week 97</time_frame>
    <description>The percentage of participants with ≥0.5 log10 change from baseline in HIV-1 RNA will be determined. The central laboratory will measure plasma HIV-1 RNA using an Abbott Real Time PCR assay with a LLOD of 40 copies/mL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants receiving DOR/ISL (given with ART) + OBT with ≥1.0 log10 decrease from baseline in HIV-1 RNA compared to DOR or ISL treatment</measure>
    <time_frame>Day 8 (baseline) and Week 25</time_frame>
    <description>The percentage of participants with ≥1.0 log10 change from baseline in HIV-1 RNA will be determined. The central laboratory will measure plasma HIV-1 RNA using an Abbott Real Time PCR assay with a LLOD of 40 copies/mL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants receiving DOR/ISL (given with ART) + OBT with ≥1.0 log10 decrease from baseline in HIV-1 RNA compared to DOR or ISL treatment</measure>
    <time_frame>Day 1 (baseline) and Week 49</time_frame>
    <description>The percentage of participants with ≥1.0 log10 change from baseline in HIV-1 RNA will be determined. The central laboratory will measure plasma HIV-1 RNA using an Abbott Real Time PCR assay with a LLOD of 40 copies/mL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants receiving DOR/ISL (given with ART) + OBT with ≥1.0 log10 decrease from baseline in HIV-1 RNA compared to DOR or ISL treatment</measure>
    <time_frame>Day 1 (baseline) and Week 97</time_frame>
    <description>The percentage of participants with ≥1.0 log10 change from baseline in HIV-1 RNA will be determined. The central laboratory will measure plasma HIV-1 RNA using an Abbott Real Time PCR assay with a LLOD of 40 copies/mL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change from baseline in HIV-1 RNA following treatment with DOR/ISL (given with ART) + OBT</measure>
    <time_frame>Day 8 (baseline) and Week 25</time_frame>
    <description>The mean change from baseline in HIV-1 RNA will be determined. The central laboratory will measure plasma HIV-1 RNA using an Abbott Real Time PCR assay with a LLOD of 40 copies/mL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change from baseline in HIV-1 RNA following treatment with DOR/ISL (given with ART) + OBT</measure>
    <time_frame>Day 1 (baseline) and Week 49</time_frame>
    <description>The mean change from baseline in HIV-1 RNA will be determined. The central laboratory will measure plasma HIV-1 RNA using an Abbott Real Time PCR assay with a LLOD of 40 copies/mL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change from baseline in HIV-1 RNA following treatment with DOR/ISL (given with ART) + OBT</measure>
    <time_frame>Day 8 (baseline) and Week 97</time_frame>
    <description>The mean change from baseline in HIV-1 RNA will be determined. The central laboratory will measure plasma HIV-1 RNA using an Abbott Real Time PCR assay with a LLOD of 40 copies/mL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants receiving DOR/ISL (given with ART) + OBT with HIV-1 RNA &lt;200 copies mL</measure>
    <time_frame>Day 8 (baseline) and Week 25</time_frame>
    <description>The percentage of participants with HIV-1 RNA &lt;200 copies mL will be determined. The central laboratory will measure plasma HIV-1 RNA using an Abbott Real Time PCR assay with a LLOD of 40 copies/mL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants receiving DOR/ISL (given with ART) + OBT with HIV-1 RNA &lt;200 copies mL</measure>
    <time_frame>Day 1 (baseline) and Week 49</time_frame>
    <description>The percentage of participants with HIV-1 RNA &lt;200 copies mL will be determined. The central laboratory will measure plasma HIV-1 RNA using an Abbott Real Time PCR assay with a LLOD of 40 copies/mL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants receiving DOR/ISL (given with ART) + OBT with HIV-1 RNA &lt;200 copies mL</measure>
    <time_frame>Day 1 (baseline) and Week 97</time_frame>
    <description>The percentage of participants with HIV-1 RNA &lt;200 copies mL will be determined. The central laboratory will measure plasma HIV-1 RNA using an Abbott Real Time PCR assay with a LLOD of 40 copies/mL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants receiving DOR/ISL (given with ART) + OBT with HIV-1 RNA &lt;50 copies mL</measure>
    <time_frame>Day 8 (baseline) and Week 25</time_frame>
    <description>The percentage of participants with HIV-1 RNA &lt;50 copies mL will be determined. The central laboratory will measure plasma HIV-1 RNA using an Abbott Real Time PCR assay with a LLOD of 40 copies/mL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants receiving DOR/ISL (given with ART) + OBT with HIV-1 RNA &lt;50 copies mL</measure>
    <time_frame>Day 1 (baseline) and Week 49</time_frame>
    <description>The percentage of participants with HIV-1 RNA &lt;50 copies mL will be determined. The central laboratory will measure plasma HIV-1 RNA using an Abbott Real Time PCR assay with a LLOD of 40 copies/mL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants receiving DOR/ISL (given with ART) + OBT with HIV-1 RNA &lt;50 copies mL</measure>
    <time_frame>Day 1 (baseline) and Week 97</time_frame>
    <description>The percentage of participants with HIV-1 RNA &lt;50 copies mL will be determined. The central laboratory will measure plasma HIV-1 RNA using an Abbott Real Time PCR assay with a LLOD of 40 copies/mL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants receiving DOR/ISL (given with ART) + OBT with HIV-1 RNA &lt;40 copies mL</measure>
    <time_frame>Day 8 (baseline) and Week 25</time_frame>
    <description>The percentage of participants with HIV-1 RNA &lt;40 copies mL will be determined. The central laboratory will measure plasma HIV-1 RNA using an Abbott Real Time PCR assay with a LLOD of 40 copies/mL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants receiving DOR/ISL (given with ART) + OBT with HIV-1 RNA &lt;40 copies mL</measure>
    <time_frame>Day 1 (baseline) and Week 49</time_frame>
    <description>The percentage of participants with HIV-1 RNA &lt;40 copies mL will be determined. The central laboratory will measure plasma HIV-1 RNA using an Abbott Real Time PCR assay with a LLOD of 40 copies/mL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants receiving DOR/ISL (given with ART) + OBT with HIV-1 RNA &lt;40 copies mL</measure>
    <time_frame>Day 1 (baseline) and Week 97</time_frame>
    <description>The percentage of participants with HIV-1 RNA &lt;40 copies mL will be determined. The central laboratory will measure plasma HIV-1 RNA using an Abbott Real Time PCR assay with a LLOD of 40 copies/mL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prevalence of viral drug resistance to DOR</measure>
    <time_frame>Week 25</time_frame>
    <description>The prevalence of viral drug resistance to DOR will be determined. Viral resistance testing will be performed by the central laboratory.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prevalence of viral drug resistance to DOR</measure>
    <time_frame>Week 49</time_frame>
    <description>The prevalence of viral drug resistance to DOR will be determined. Viral resistance testing will be performed by the central laboratory.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prevalence of viral drug resistance to ISL</measure>
    <time_frame>Week 25</time_frame>
    <description>The prevalence of viral drug resistance to ISL will be determined. Viral resistance testing will be performed by the central laboratory.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prevalence of viral drug resistance to ISL</measure>
    <time_frame>Week 49</time_frame>
    <description>The prevalence of viral drug resistance to ISL will be determined. Viral resistance testing will be performed by the central laboratory.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prevalence of viral drug resistance to optimized background therapy (OBT) components</measure>
    <time_frame>Week 25</time_frame>
    <description>The prevalence of viral drug resistance to OBT components will be determined. Viral resistance testing will be performed by the central laboratory.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prevalence of viral drug resistance to OBT components</measure>
    <time_frame>Week 49</time_frame>
    <description>The prevalence of viral drug resistance to OBT components will be determined. Viral resistance testing will be performed by the central laboratory.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Role of baseline antiviral resistance on viral resistance-associated substitutions (RASs)</measure>
    <time_frame>Day 1 (baseline) and Week 25</time_frame>
    <description>The role of baseline antiviral resistance on viral RAS will be determined.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Role of baseline antiviral resistance on viral RASs</measure>
    <time_frame>Day 1 (baseline) and Week 49</time_frame>
    <description>The role of baseline antiviral resistance on viral RAS will be determined.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Role of baseline antiviral resistance on viral RASs</measure>
    <time_frame>Day 1 (baseline) and Week 97</time_frame>
    <description>The role of baseline antiviral resistance on viral RAS will be determined.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Role of baseline antiviral resistance on HIV-1 RNA</measure>
    <time_frame>Day 8 (baseline) and Week 25</time_frame>
    <description>The role of baseline antiviral resistance on HIV-1 RNA will be determined.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Role of baseline antiviral resistance on HIV-1 RNA</measure>
    <time_frame>Day 8 (baseline) and Week 49</time_frame>
    <description>The role of baseline antiviral resistance on HIV-1 RNA will be determined.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Role of baseline antiviral resistance on HIV-1 RNA</measure>
    <time_frame>Day 8 (baseline) and Week 97</time_frame>
    <description>The role of baseline antiviral resistance on HIV-1 RNA will be determined.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in cluster of differentiation 4+ (CD4+) T-cell counts</measure>
    <time_frame>Day 1 (baseline) and Week 25</time_frame>
    <description>The change from baseline in CD4+ T-cell counts will be determined. CD4+ T-cell counts will be determined by the central laboratory.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in CD4+ T-cell counts</measure>
    <time_frame>Day 1 (baseline) and Week 49</time_frame>
    <description>The change from baseline in CD4+ T-cell counts will be determined. CD4+ T-cell counts will be determined by the central laboratory.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in CD4+ T-cell counts</measure>
    <time_frame>Day 1 (baseline) and Week 97</time_frame>
    <description>The change from baseline in CD4+ T-cell counts will be determined. CD4+ T-cell counts will be determined by the central laboratory.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in CD4+ T-cell counts</measure>
    <time_frame>Day 8 (baseline) and Week 25</time_frame>
    <description>The change from baseline in CD4+ T-cell counts will be determined. CD4+ T-cell counts will be determined by the central laboratory.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in CD4+ T-cell counts</measure>
    <time_frame>Day 8 (baseline) and Week 49</time_frame>
    <description>The change from baseline in CD4+ T-cell counts will be determined. CD4+ T-cell counts will be determined by the central laboratory.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in CD4+ T-cell counts</measure>
    <time_frame>Day 8 (baseline) and Week 97</time_frame>
    <description>The change from baseline in CD4+ T-cell counts will be determined. CD4+ T-cell counts will be determined by the central laboratory.</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>HIV-1 Infection</condition>
  <arm_group>
    <arm_group_label>Part 1, Group 1: ISL + ART</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HTE participants with HIV-1 infection take ISL 0.75 mg once daily (QD) in combination with failing ART from Day 1 to Day 7 in Part 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1, Group 2: DOR + ART</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HTE participants with HIV-1 infection take DOR 100 mg QD in combination with failing ART from Day 1 to Day 7 in Part 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1, Group 3: DOR/ISL + ART</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HTE participants with HIV-1 infection take 100 mg DOR/0.75 mg ISL FDC QD in combination with failing ART from Day 1 to Day 7 in Part 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1, Group 4: Placebo + ART</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>HTE participants with HIV-1 infection take placebo QD in combination with failing ART from Day 1 to Day 7 in Part 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2, Group 5: Open-Label DOR/ISL + OBT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HTE participants from Groups 1 to 4 with HIV-1 infection take open-label 100 mg DOR/0.75 mg ISL + OBT in Part 2 (Day 8 to Week 97).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ISL</intervention_name>
    <description>ISL 0.75 mg capsule taken by mouth.</description>
    <arm_group_label>Part 1, Group 1: ISL + ART</arm_group_label>
    <other_name>Islatravir</other_name>
    <other_name>MK-8591</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DOR</intervention_name>
    <description>DOR 100 mg tablet taken by mouth.</description>
    <arm_group_label>Part 1, Group 2: DOR + ART</arm_group_label>
    <other_name>Doravirine</other_name>
    <other_name>MK-1439</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DOR/ISL</intervention_name>
    <description>100 mg DOR/0.75 mg ISL FDC taken by mouth.</description>
    <arm_group_label>Part 1, Group 3: DOR/ISL + ART</arm_group_label>
    <arm_group_label>Part 2, Group 5: Open-Label DOR/ISL + OBT</arm_group_label>
    <other_name>Doravirine/Islatravir</other_name>
    <other_name>MK-8591A</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo to ISL</intervention_name>
    <description>Placebo capsule matched to ISL taken by mouth.</description>
    <arm_group_label>Part 1, Group 4: Placebo + ART</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo to DOR</intervention_name>
    <description>Placebo tablet matched to DOR taken by mouth.</description>
    <arm_group_label>Part 1, Group 4: Placebo + ART</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Is HIV-1 positive.&#xD;
&#xD;
          -  Has been receiving the same baseline ART for ≥3 months prior to signing the Informed&#xD;
             Consent Form/Assent Form.&#xD;
&#xD;
          -  Weighs ≥35 kg.&#xD;
&#xD;
          -  Has at least triple-class resistance (must include nucleoside reverse transcriptase&#xD;
             inhibitor [NRTI], non-nucleoside reverse transcriptase inhibitor [NNRTI], and&#xD;
             resistance to either protease inhibitor (PI) or integrase strand transfer inhibitor&#xD;
             (InSTI), based on central laboratory-based resistance or proviral DNA resistance&#xD;
             testing at the Screening Visit, or historical resistance testing within 12 months of&#xD;
             screening.&#xD;
&#xD;
          -  Has ≤2 fully active antiretroviral drugs remaining among all antiretroviral classes&#xD;
             that can be effectively combined to form a viable regimen based on resistance,&#xD;
             tolerability, safety, drug access, or acceptability to participant.&#xD;
&#xD;
          -  If female, is not pregnant or breastfeeding, and is: 1) not a woman of childbearing&#xD;
             potential (WOCBP); 2) a WOCBP and uses an acceptable method of contraception/is&#xD;
             abstinent; or 3) a WOCBP and has a negative pregnancy test within 24 hours of the&#xD;
             first dose of study medication.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Has HIV type 2 (HIV-2) infection.&#xD;
&#xD;
          -  Has hypersensitivity or other contraindication to any of the components of the study&#xD;
             interventions as determined by the investigator.&#xD;
&#xD;
          -  Has hepatitis B virus (HBV) co-infection (defined as hepatitis B surface antigen&#xD;
             [HBsAg]-positive or HBV deoxyribonucleic acid [DNA] positive) and is not currently&#xD;
             being treated for HBV.&#xD;
&#xD;
          -  Has a history or current evidence of any condition, therapy (including active TB&#xD;
             co-infection), laboratory abnormality or other circumstance (including drug or alcohol&#xD;
             abuse or dependence) that might, in the opinion of the investigator, confound the&#xD;
             results of the study or interfere with study participation for the full study&#xD;
             duration.&#xD;
&#xD;
          -  Is taking or is anticipated to require any of the prohibited therapies from the&#xD;
             Screening Visit and throughout the study treatment period.&#xD;
&#xD;
          -  Is taking DOR as part of his/her current failing antiretroviral regimen.&#xD;
&#xD;
          -  Is taking efavirenz (EFV), etravirine, or nevirapine.&#xD;
&#xD;
          -  Is currently participating in or has participated in an interventional clinical study&#xD;
             with an investigational compound or device from the Screening Visit through the study&#xD;
             treatment period.&#xD;
&#xD;
          -  Is female and is expecting to conceive or donate eggs at any time during the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Toll Free Number</last_name>
    <phone>1-888-577-8839</phone>
    <email>Trialsites@merck.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Alabama at Birmingham 1917 Research Clinic ( Site 4031)</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35222</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Men's Health Foundation ( Site 4018)</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90069</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>310-550-1010</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Palmtree Clinical Research, Inc. ( Site 4016)</name>
      <address>
        <city>Palm Springs</city>
        <state>California</state>
        <zip>92262</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>760-778-7799</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Yale School of Medicine ( Site 4007)</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06510</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Georgetown University Hospital ( Site 4015)</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>202-444-0371</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Kinder Medical Group ( Site 4014)</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33133</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>786-497-4000</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Orlando Immunology Center ( Site 4012)</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32803</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>407-647-3960</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Triple O Research Institute, P.A. ( Site 4020)</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33407</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>561-855-7871</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chatham County Health Department ( Site 4029)</name>
      <address>
        <city>Savannah</city>
        <state>Georgia</state>
        <zip>31410</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>912-651-1978</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Howard Brown Health Center ( Site 4006)</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60613</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>312-451-6830</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Northstar Healthcare ( Site 4004)</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60657</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>773-296-2400</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Maryland ( Site 4023)</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>410-706-3727</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>The University of Mississippi Medical Center ( Site 4036)</name>
      <address>
        <city>Jackson</city>
        <state>Mississippi</state>
        <zip>39216-4505</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>518-505-0701</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Saint Michael's Medical Center-Research - Infectious Disease ( Site 4035)</name>
      <address>
        <city>Newark</city>
        <state>New Jersey</state>
        <zip>07102</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>973-877-2735</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Icahn School of Medicine at Mount Sinai ( Site 4000)</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>212-824-7821</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of North Carolina at Chapel Hill ( Site 4026)</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Saint Hope Foundation, Inc. ( Site 4034)</name>
      <address>
        <city>Bellaire</city>
        <state>Texas</state>
        <zip>77401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>713-839-7111</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>North Texas Infectious Diseases Consultants, PA ( Site 4005)</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>214-276-5618</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dr. Peter Shalit, MD ( Site 4002)</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>206-624-1441</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Holdsworth House Medical Practice ( Site 5300)</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <zip>2000</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+61293317228</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>St Vincent's Hospital ( Site 5309)</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <zip>2010</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+61283821111</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Holdsworth House Medical Practice - Brisbane ( Site 5312)</name>
      <address>
        <city>Brisbane</city>
        <state>Queensland</state>
        <zip>4006</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+61 7 3894 0794</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Monash Health-Monash Medical Centre ( Site 5313)</name>
      <address>
        <city>Clayton</city>
        <state>Victoria</state>
        <zip>3168</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+61 3 9594 6666</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Alfred Hospital ( Site 5304)</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3004</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+61390762296</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Vancouver ID Research and Care Centre Society ( Site 4100)</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V6Z 2C7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>6046426429</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hamilton Health Sciences ( Site 4115)</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8L 2X2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>9055215075</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ottawa Hospital Research Institute ( Site 4111)</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1H 8L6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+16137396866</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Toronto General Hospital - University Health Network ( Site 4105)</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2N2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>4163404800x2240</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>McGill University Health Center - Research Institute-CVIS Clinical Research Unit ( Site 4102)</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H4A 3J1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>5148432090</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Dr. Hernan Henriquez Aravena ( Site 4405)</name>
      <address>
        <city>Temuco</city>
        <state>Araucania</state>
        <zip>4781151</zip>
        <country>Chile</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+56996420376</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fundacion Arriaran ( Site 4401)</name>
      <address>
        <city>Santiago</city>
        <state>Region M. De Santiago</state>
        <zip>8360159</zip>
        <country>Chile</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Centro Cardiovascular Cardiosur ( Site 4407)</name>
      <address>
        <city>Santiago</city>
        <state>Region M. De Santiago</state>
        <zip>8910259</zip>
        <country>Chile</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+56963108092</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinica Colsanitas S.A. Sede Clinica Universitaria Colombia ( Site 4306)</name>
      <address>
        <city>Bogota</city>
        <state>Distrito Capital De Bogota</state>
        <zip>111321</zip>
        <country>Colombia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+573114779819</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fundacion Valle del Lili ( Site 4301)</name>
      <address>
        <city>Cali</city>
        <state>Valle Del Cauca</state>
        <zip>760032</zip>
        <country>Colombia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+573155614943</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hopital Edouard Herriot ( Site 4726)</name>
      <address>
        <city>Lyon</city>
        <state>Ain</state>
        <zip>69003</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+33472110230</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>A.P.H. Paris. Hopital Bichat Claude Bernard ( Site 4724)</name>
      <address>
        <city>Paris</city>
        <state>Ain</state>
        <zip>75018</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+33140257057</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de Nice Hopital Archet 1 ( Site 4703)</name>
      <address>
        <city>Nice</city>
        <state>Alpes-Maritimes</state>
        <zip>06202</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+33413423423</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hopital Europeen Marseille ( Site 4717)</name>
      <address>
        <city>Marseille</city>
        <state>Bouches-du-Rhone</state>
        <zip>13003</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+33413423423</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de Bordeaux- Hopital Saint Andre ( Site 4715)</name>
      <address>
        <city>Bordeaux</city>
        <state>Gironde</state>
        <zip>33075</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+33556795679</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de Rouen ( Site 4705)</name>
      <address>
        <city>Rouen</city>
        <state>Haute-Normandie</state>
        <zip>76031</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+33232888739</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de Montpellier - Hopital Saint-Eloi ( Site 4721)</name>
      <address>
        <city>Montpellier</city>
        <state>Herault</state>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+33467337220</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de Tourcoing ( Site 4700)</name>
      <address>
        <city>Tourcoing</city>
        <state>Nord</state>
        <zip>59208</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+33320694617</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hopital Avicenne ( Site 4702)</name>
      <address>
        <city>Bobigny</city>
        <state>Seine-Saint-Denis</state>
        <zip>93000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+33148955146</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hopital Hotel Dieu [Paris, France] ( Site 4723)</name>
      <address>
        <city>Paris</city>
        <zip>75004</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+33142348836</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>A.P.H. Paris, Hopital Saint Louis ( Site 4714)</name>
      <address>
        <city>Paris</city>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+33142499066</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medizinische Hochschule Hannover ( Site 4612)</name>
      <address>
        <city>Hannover</city>
        <state>Niedersachsen</state>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+495115325155</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Bonn ( Site 4600)</name>
      <address>
        <city>Bonn</city>
        <state>Nordrhein-Westfalen</state>
        <zip>53127</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+49222815421</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Essen ( Site 4607)</name>
      <address>
        <city>Essen</city>
        <state>Nordrhein-Westfalen</state>
        <zip>45122</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+492017233878</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>ZIBP-Zentrum fur Infektiologie Berlin Prenzlauer Berg GmbH ( Site 4603)</name>
      <address>
        <city>Berlin</city>
        <zip>10439</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+4930233212870</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>EPIMED GmbH ( Site 4608)</name>
      <address>
        <city>Berlin</city>
        <zip>10787</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+4930265 583 70</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>ICH Study Center GmbH &amp; Co.KG ( Site 4609)</name>
      <address>
        <city>Hamburg</city>
        <zip>20146</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+494028407370</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero Universitaria di Modena Policlinico ( Site 5004)</name>
      <address>
        <city>Modena</city>
        <state>Emilia-Romagna</state>
        <zip>41124</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+39059422466</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ospedale San Gerardo ASST Monza ( Site 5012)</name>
      <address>
        <city>Monza</city>
        <state>Monza E Brianza</state>
        <zip>20900</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+390392339315</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fondazione IRCCS Ca' Granda-Ospedale Maggiore Policlinico ( Site 5001)</name>
      <address>
        <city>Milano</city>
        <zip>20122</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+390255034763</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universita' Vita Salute. Ospedale San Raffaele ( Site 5002)</name>
      <address>
        <city>Milano</city>
        <zip>20127</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+390226437934</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera San Paolo ( Site 5003)</name>
      <address>
        <city>Milano</city>
        <zip>20142</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+390281843045</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>ASST Fatebenefratelli-Ospedale Sacco ( Site 5000)</name>
      <address>
        <city>Milano</city>
        <zip>20157</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+390239043490</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>IRCCS Policlinico San Matteo ( Site 5010)</name>
      <address>
        <city>Pavia</city>
        <zip>27100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>0382502403</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Istituto Nazionale per Le Malattie Infettive Lazzaro Spallanzani ( Site 5005)</name>
      <address>
        <city>Roma</city>
        <zip>00149</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+390655170546</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Policlinico Gemelli Instituto di Clinica Chirurgica ( Site 5006)</name>
      <address>
        <city>Roma</city>
        <zip>00168</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+390630154945</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Center Hospital of the National Center for Global Health and Medicine ( Site 5401)</name>
      <address>
        <city>Tokyo</city>
        <zip>162-8655</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81332027181</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Pusan National University Hospital ( Site 5503)</name>
      <address>
        <city>Busan</city>
        <state>Pusan-Kwangyokshi</state>
        <zip>49241</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+82512407673</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Severance Hospital Yonsei University Health System ( Site 5500)</name>
      <address>
        <city>Seoul</city>
        <zip>03722</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+82222281974</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Catholic University of Korea. Seoul St. Mary s Hospital ( Site 5502)</name>
      <address>
        <city>Seoul</city>
        <zip>06591</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+82222586002</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Via Libre ( Site 4500)</name>
      <address>
        <city>Lima</city>
        <zip>15001</zip>
        <country>Peru</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+51944817657</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>INMENSA ( Site 4506)</name>
      <address>
        <city>Lima</city>
        <zip>15046</zip>
        <country>Peru</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+51942128602</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Policlinico Universidad Nacional Mayor de San Marcos ( Site 4501)</name>
      <address>
        <city>Lima</city>
        <zip>15081</zip>
        <country>Peru</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>51961072186</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital de Nossa Senhora da Oliveira- EPE ( Site 4905)</name>
      <address>
        <city>Guimaraes</city>
        <state>Braga</state>
        <zip>4835-044</zip>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+351253540330</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Dr. Fernando Fonseca, EPE - Amadora/Sintra ( Site 4902)</name>
      <address>
        <city>Amadora</city>
        <state>Lisboa</state>
        <zip>2720-276</zip>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+351214348404</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centro Hospitalar de Lisboa Norte Hospital de Santa Maria ( Site 4913)</name>
      <address>
        <city>Lisboa</city>
        <zip>1649-035</zip>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+351217805000</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Geral de Santo Antonio ( Site 4908)</name>
      <address>
        <city>Porto</city>
        <zip>4099-001</zip>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+351222077500</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centro Hospitalar de Sao Joao. EPE - Hospital de Sao Joao ( Site 4907)</name>
      <address>
        <city>Porto</city>
        <zip>4200-319</zip>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+351225512100</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>HOPE Clinical Research ( Site 5700)</name>
      <address>
        <city>San Juan</city>
        <zip>00909</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>7872687078</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Saint Petersburg Center for Prophylactic of AIDS and Inf. Diseases ( Site 5101)</name>
      <address>
        <city>Saint Petersburg</city>
        <state>Leningradskaya Oblast</state>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+78124959976</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Infectious Clinical Hospital #2 ( Site 5114)</name>
      <address>
        <city>Moscow</city>
        <state>Moskva</state>
        <zip>105275</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+79037143865</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Gbuz Samarskiy Oblastnoy Klinicheskiy Tsentr Profilaktiki I Bor'by So Spid ( Site 5113)</name>
      <address>
        <city>Samara</city>
        <state>Samarskaya Oblast</state>
        <zip>443124</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+78463743174</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>FGU Republican Clinical Infectious Hospital of Roszdrav ( Site 5100)</name>
      <address>
        <city>Saint Petersburg</city>
        <state>Sankt-Peterburg</state>
        <zip>196645</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+78124644340</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Smolensk Center On Aids And Infectious Diseases Prophylaxis ( Site 5115)</name>
      <address>
        <city>Smolensk</city>
        <state>Smolenskaya Oblast</state>
        <zip>214006</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+74812219616</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Regional Center for Prevent. and Control of AIDS and Inf. Diseases ( Site 5106)</name>
      <address>
        <city>Yekaterinburg</city>
        <state>Sverdlovskaya Oblast</state>
        <zip>620102</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Republican Clinical Hospital of Infectious Diseases n. a. A.F.Agafonov ( Site 5104)</name>
      <address>
        <city>Kazan</city>
        <state>Tatarstan, Respublika</state>
        <zip>420140</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+78432678117</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>FARMOVS ( Site 4805)</name>
      <address>
        <city>Bloemfontein</city>
        <state>Free State</state>
        <zip>9301</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+27514013181</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Wits Clinical HIV Research Unit ( Site 4804)</name>
      <address>
        <city>Johannesburg</city>
        <state>Gauteng</state>
        <zip>2041</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+27112768800</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ezintsha ( Site 4806)</name>
      <address>
        <city>Johannesburg</city>
        <state>Gauteng</state>
        <zip>2193</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+27113585300</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>King Edward Hospital ( Site 4802)</name>
      <address>
        <city>Durban</city>
        <state>Kwazulu-Natal</state>
        <zip>4013</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+27312611093</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Germans Trias i Pujol ( Site 5600)</name>
      <address>
        <city>Badalona</city>
        <state>Barcelona</state>
        <zip>08916</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+34934978849</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic i Provincial ( Site 5601)</name>
      <address>
        <city>Barcelona</city>
        <state>Cataluna</state>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+34932275430</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Santa Lucia ( Site 5603)</name>
      <address>
        <city>Cartagena</city>
        <state>Murcia, Region De</state>
        <zip>30202</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+34968128602951303</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Paz ( Site 5604)</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+34917277099</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dnipropetrovsk Regional Center of Socially Significant Diseases ( Site 5619)</name>
      <address>
        <city>Dnipro</city>
        <state>Dnipropetrovska Oblast</state>
        <zip>49115</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+380993348511</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Regional Clinical Infectious Hospital ( Site 5614)</name>
      <address>
        <city>Kharkiv</city>
        <state>Kharkivska Oblast</state>
        <zip>61096</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+380996410027</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kherson City Clinical Hospital n.a. Y.Y. Karabelesh ( Site 5620)</name>
      <address>
        <city>Kherson</city>
        <state>Khersonska Oblast</state>
        <zip>73000</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+380676474171</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institute of Epidemiology and Infect Diseases of the NAMS of Ukraine ( Site 5615)</name>
      <address>
        <city>Kyiv</city>
        <state>Kyivska Oblast</state>
        <zip>03038</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+380503301455</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mykolaiv center of paliative assistance and integrated services ( Site 5621)</name>
      <address>
        <city>Mykolaiv</city>
        <state>Mykolaivska Oblast</state>
        <zip>54003</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+380934497212</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>MNE Odesa Regional Center of Socially Significant Diseases ( Site 5611)</name>
      <address>
        <city>Odesa</city>
        <state>Odeska Oblast</state>
        <zip>65014</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+380687932254</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>MI Vinnytsia Regional Center of AIDS Prevention and Care ( Site 5618)</name>
      <address>
        <city>Berezina</city>
        <state>Vinnytska Oblast</state>
        <zip>23222</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+380672525050</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kyiv City Clinical Hospital 5 ( Site 5616)</name>
      <address>
        <city>Kyiv</city>
        <zip>03115</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+380677492242</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Western General Hospital ( Site 5201)</name>
      <address>
        <city>Edinburgh</city>
        <state>Edinburgh, City Of</state>
        <zip>EH4 2XU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>441315372852</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Royal Free Hospital ( Site 5202)</name>
      <address>
        <city>London</city>
        <state>England</state>
        <zip>NW3 2QG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+442074726232</phone>
    </contact>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Canada</country>
    <country>Chile</country>
    <country>Colombia</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>Peru</country>
    <country>Portugal</country>
    <country>Puerto Rico</country>
    <country>Russian Federation</country>
    <country>South Africa</country>
    <country>Spain</country>
    <country>Ukraine</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>January 15, 2020</study_first_submitted>
  <study_first_submitted_qc>January 15, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 18, 2020</study_first_posted>
  <last_update_submitted>November 11, 2021</last_update_submitted>
  <last_update_submitted_qc>November 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Islatravir</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf</ipd_description>
    <ipd_url>http://engagezone.msd.com/ds_documentation.php</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

